Korro Bio, Inc. - KRRO STOCK NEWS

Korro Bio has been added to the Russell 2000, Russell 3000, and Russell Microcap Indexes as part of the annual reconstitution effective July 1, 2024. This inclusion is based on market capitalization rankings determined by FTSE Russell. Korro Bio's CEO, Dr. Ram Aiyar, emphasized their commitment to advancing their drug candidate, KRRO-110, for Alpha-1 Antitrypsin Deficiency, with plans to file with regulatory agencies in the second half of 2024 and an interim data readout in the second half of 2025. The inclusion in these indexes is expected to enhance value for Korro's stakeholders.

Korro Bio (Nasdaq: KRRO) will participate in several significant investor and scientific conferences in June 2024.

CEO Ram Aiyar, Ph.D., and CFO Vineet Agarwal will present at the Jefferies Global Healthcare Conference on June 6 at 2:00 p.m. ET.

CMO Dr. Kemi Olugemo will discuss Korro's lead RNA editing oligonucleotide candidate, KRRO-110, for treating Alpha-1 Antitrypsin Deficiency at the 2024 Alpha-1 Foundation National Conference on June 8 at 11:20 a.m. ET.

Senior VP Venkat Krishnamurthy, Ph.D., will participate in the 5th Annual RNA Editing Summit on June 20, engaging in a roundtable discussion and giving a presentation on the OPERA platform and its clinical progress.

The Jefferies presentation will be webcast live, with a replay available for 30 days on Korro's website.

Korro Bio presented new preclinical data on KRRO-110 at the 2024 American Thoracic Society International Conference. The data demonstrated sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to over 60µM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model. Notably, KRRO-110 showed 35µM of M-AAT one week post the first dose, rising to 45µM of M-AAT by week 13. This data suggests KRRO-110's potential as a best-in-class therapeutic for AATD. Korro plans to submit a regulatory filing for a first-in-human study in the second half of 2024.

Korro Bio (Nasdaq: KRRO) reported its financial results for Q1 2024 and announced the appointment of Dr. Kemi Olugemo as Chief Medical Officer. Significant milestones include a $70 million private placement completed in April 2024, increasing cash reserves to $206 million. This funding extends Korro's cash runway into the second half of 2026. Pipeline progress includes plans for a regulatory filing for KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD), in the latter half of 2024. Interim readout for KRRO-110 is expected in H2 2025, with trial completion in 2026. Financial highlights show a decrease in cash from $166.1 million to $138.8 million and a net loss of $19.6 million for Q1 2024, unchanged from the previous year. R&D expenses dropped to $13.6 million, while G&A expenses rose to $7.9 million.

Korro Bio, Inc. announces a $70 million private placement led by Deep Track Capital and other healthcare investors. The financing is expected to close on April 22, 2024, providing pro-forma cash of approximately $236 million. Korro plans to use the proceeds for regulatory filings, interim readouts, and study completions for its genetic medicines. The company aims to advance its pipeline programs and platform development, with a focus on delivery and machine learning.

Korro Bio, Inc. announces CEO and executives' participation in upcoming investor conferences to discuss progress on KRRO-110, a promising candidate for AATD treatment.

Korro Bio, Inc. (KRRO) reports strong financials for 2023, with a cash balance of $166 million, anticipating regulatory filing for KRRO-110 in AATD patients in late 2024. The company demonstrated over 50% editing using GalNAc conjugates in a preclinical mouse model and achieved significant milestones in pipeline development.

Korro Bio, Inc. (KRRO) announced CEO Ram Aiyar will present at TD Cowen 44th Annual Health Care Conference. CFO and CSO to participate. Webcast available on Korro's website.

Korro Bio, Inc. presented new data for KRRO-110 at the J.P. Morgan Healthcare Conference, showcasing its potential as a best-in-class therapeutic for AATD patients. The company reported progress across its RNA editing portfolio, demonstrating high specificity and sustained protein correction in preclinical mouse models. Korro's proprietary RNA editing platform, OPERA™, has shown potential in creating de novo mutations to alter protein function, with promising results in activating transcription factors and modulating ion channels.